Chris Thomajan

Chris Thomajan has been a CFO for over 30 years in a variety of industries, including: biotech, medtech, software, digital media, Internet services and investment banking.

Chris was a founding partner of America’s Growth Capital, a boutique investment bank focused on emerging growth technology companies. He was the early stage CFO/VP Operations for Asurion Corporation which is a closely held, multi-billion-dollar private company. He was also the founding CFO for a pioneering Internet company, Delphi Internet Services, which was acquired by News Corporation in 1993.

Since joining TechCXO in 2007, Chris has worked with outstanding companies such as Cyteir Therapeutics (CYT – IPO in 2021), Decibel Therapeutics (DBTX – IPO in 2021), Relay Therapeutics (RLAY – IPO in 2020), Keros Therapeutics (KROS – IPO in 2020), Mashable, Mascoma Corp., Adheron (acquired by Roche in 2015), Catabasis Pharmaceuticals (CATB – IPO in 2015), and Ektron (acquired by Accel/KKR in December 2014). Current clients include Valenza Biotech, QurAlis Corporation and EnClear Therapies.